Recordati First-Half Revenue Rises 8.9% on Pharmaceutical Sales

July 14 (Bloomberg) -- Recordati SpA, Italy’s biggest publicly traded drugmaker, said first-half revenue advanced 8.9 percent, led by pharmaceutical sales and international business.

Sales rose to 379.3 million euros ($531.3 million) from the first six months of 2008, Milan-based Recordati said today in a statement issued by the Italian exchange. Pharmaceutical sales gained 10 percent as pharmaceutical-chemical sales declined. Recordati’s international revenue rose 13 percent as Italian sales advanced 1.2 percent.

The company didn’t publish figures for earnings or give forecasts.

Recordati has risen 17 percent in Milan this year, giving the company a market value of 951 million euros. The stock traded at 4.55 euros, up 0.9 percent, at 10:40 a.m.

To contact the reporter on this story: Armorel Kenna in Milan at akenna@bloomberg.net

To contact the editor responsible for this story: Benedikt Kammel at bkammel@bloomberg.net